Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5938696 | 1.00 | POLB (0.53) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL9067214 | 1.00 | POLB (0.53) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL5938686 | 1.00 | POLB (0.53) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL13324264 | 1.00 | POLB (0.53) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL18769553 | 0.86 | ALDH1A1 (0.49) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL31629999 | 0.82 | PKM (0.61) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL29657316 | 0.82 | PKM (0.61) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL9066623 | 0.82 | PKM (0.50) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL9066627 | 0.82 | PKM (0.50) | POLBPKMALDH1A1HTTCYP2C19 | |
| SCHEMBL18769554 | 0.81 | POLB (0.49) | POLBPKMALDH1A1HTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709472-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-7709472-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-20080234256-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | US | disclosed |
| US-20080234256-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234256-A1 | Antibacterial Agents | NRDC, NCF1, NQO2 | POLB 203/4885PKM 4339/4885ALDH1A1 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.